What Is Sivextro Used For?
Sivextro (tedizolid phosphate) treats acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria like Staphylococcus aureus, Streptococcus pyogenes, and others. It's approved for adults and given as a 6-day IV or oral course.[1]
How Does It Target Skin Infections?
Sivextro inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effective against gram-positive pathogens common in skin infections like cellulitis, wound infections, or abscesses. Clinical trials showed 6-day treatment noninferior to 10-day linezolid, with 92-96% success rates at end-of-therapy.[1][2]
What Skin Conditions Does It Cover?
ABSSSI includes:
- Cellulitis or erysipelas (>75 cm²)
- Wound infection (>10 cm)
- Major cutaneous abscess (>75 cm²)
It does not treat gram-negative, fungal, or viral skin infections.[1]
Common Alternatives for Skin Infections?
| Drug | Duration | Key Notes |
|------|----------|-----------|
| Linezolid (Zyvox) | 10-14 days | Similar mechanism; oral/IV; higher cost, myelosuppression risk |
| Vancomycin | 7-14 days | IV only; monitors levels; MRSA coverage |
| Daptomycin (Cubicin) | 2-14 days | IV; muscle pain risk; not oral |
| Cephalexin | 7-10 days | Oral; gram-positive; cheaper for mild cases |
Sivextro edges out on shorter duration and oral switch.[2]
Who Should Avoid Sivextro for Skin Issues?
Contraindicated in hypersensitivity. Caution in renal/hepatic impairment, pregnancy (limited data), or with QT-prolonging drugs. Side effects: nausea (8%), headache (6%), diarrhea (4%); rare myelosuppression.[1]
When Does the Sivextro Patent Expire?
U.S. patents expire around 2027-2031; generics possible post-2027 if challenges succeed. Check DrugPatentWatch.com for updates.[3]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205435s000lbl.pdf
[2] ESTABLISH-1/2 Trials: https://www.nejm.org/doi/full/10.1056/NEJMoa1401830
[3] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/SIVEXTRO